Specific features of the immune status of patients with bronchial asthma and COVID-19.

Айгерим Баубекова, Рафаил Розенсон

2022

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.54500/2790-1203.112.2.2022.17-26
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Aim: to study the specific features of changes in the immune status of patients with bronchial asthma and COVID-19 Materials and methods: Study date: 08.2021-04.22. Study design: a review. A literature review was conducted in the PubMed, Scopus, Web of Science, MEDLINE, EMBASE, Cochrane Library databases, as well as a manual search for suitable articles. We analyzed immunological differences that may influence the pathophysiological process in patients with COVID-19 and asthma, including immunoglobulins, interferons, and local immune cells. Results: Through a study of 39 studies, including retrospective analyses, it was found that it is still unknown whether the asthma phenotype contributes to some protection of patients from COVID-19. Several immune differences have been found between COVID-19 patients with and without comorbid asthma: decreased levels of pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6, and IL-12), impaired production of type I and III interferons ( IFN-α, IFN-β, IFN-λ), which is a priority produced to fight the COVID-19 virus. Conclusions: Several of the research that have been reported so far are retrospective and do not differentiate between asthma phenotypes. Extensive therapeutic and immunological markers are severely lacking. To obtain a better knowledge of the immunological and metabolic link between COVID-19 and asthma, comprehensive endotyping of individuals with COVID-19 and asthma would be necessary. Furthermore, further information on the transcriptional and translational level of receptors modulation is needed at the level of virus-host contacts in relation to the virus's cellular entrance process. Furthermore, longterm prospective investigations are lacking. Additional knowledge on COVID-19 in asthmatic and allergy individuals is fast becoming available. Recent asthma treatment guidelines in the framework of COVID-19 should not be modified, according to current thinking. If indicated, patients will receive pharmacological therapy based on guidelines, including ICSs and biological treatments.